Key facts
- SentryX’s last known valuation is $38.7M (Apr 2021).
- It has raised $3.8M.
- Notable investors include European Innovation Council, Utrecht Holdings, Utrecht Health Seed Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for SentryX
- ·The full record, as it builds
Funding rounds
No funding rounds for SentryX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SentryX
Operator of a non-opioid therapeutic platform intended for the treatment of acute pain following musculoskeletal surgery. The company's platform utilizes localized pain management strategies that reduce reliance on systemic opioid-based treatments with advanced drug delivery mechanisms to target affected areas directly, enabling healthcare providers to offer safer and more effective pain relief for patients undergoing orthopedic procedures.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2017
- Employees
- 21
- Website
- sentryx.nl/
- Ownership
- Privately Held (backing)
SentryX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SentryX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SentryX in its N-PORT filings yet. We sweep new filings monthly.